teaser
Schering-Plough has announced that the US Food and Drug Administration has accepted the filing for review of the New Drug Application (NDA) for asenapine, a fast-dissolving, sublingual tablet.
The company is seeking marketing approval from the FDA for the treatment of schizophrenia and acute mania or mixed episodes associated with Bipolar Disorder.
↓Article continues below this sponsored advert↓
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
↑Advertisement↑
In accepting the NDA, the FDA indicated that asenapine would receive a standard review.
The clinical trial programme thus far has consisted of schizophrenia and bipolar mania trials involving nearly 3,000 patients.
Schering-Plough acquired asenapine through its combination with Organon BioSciences last week.
